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Abstract
Background: Angiogenesis plays an important role in the development and progression of tumors. Kallistatin
exerts anti-angiogenic and anti-inflammatory activities that may be effective in inhibiting tumor metastasis.
We investigated the antitumor effect of lentivirus-mediated kallistatin gene transfer in a syngeneic murine tumor
model.
Methods: Lentiviral vector encoding kallistatin (LV-Kallistatin) was constructed. The expression of kallistatin was
verified by enzyme-linked immunosorbent assay (ELISA), and the bioactivity of kallistatin was determined by using
cell proliferation, migration, and invasion assays. In addition, antitumor effects of LV-Kallistatin were evaluated by
the intravenous injection of virus into tumor-bearing mice.
Results: The conditioned medium from LV-Kallistatin-treated cells inhibited the migration and proliferation of
endothelial cells. Meanwhile, it also reduced the migration and invasion of tumor cells. In the experimental lung
metastatic model, tumor-bearing mice receiving LV-Kallistatin had lower tumor nodules and longer survival than
those receiving control virus or saline. Moreover, the microvessel densities, the levels of vascular endothelial
growth factor (VEGF), tumor necrosis factor (TNF)-a, and nuclear factor B (NF-B) transcriptional activity were
reduced in the LV-Kallistatin-treated mice.
Conclusion: Results of this study showed that systemic administration of lentiviral vectors encoding kallistatin
inhibited the growth of metastatic tumor and prolonged the survival of tumor-bearing mice. These results suggest
that gene therapy using lentiviruses carrying the kallistatin gene, which exerts anti-angiogenic and anti-
inflammatory activities, represents a promising strategy for the treatment of lung cancer.
Background
Kallistatin, a serine proteinase inhibitor, is first identified
as a tissue kallikrein-binding protein, and has emerged
as a novel inhibitor of angiogenesis. Kallistatin exerts a
variety of biological effects in physiologic and pathologic
responses, such as blood pressure regulation, inflamma-
tion and anti-angiogenesis [1-5]. It has been reported
that kallistatin inhibited vascular endothelial growth fac-
tor (VEGF)-induced or basic fibroblast growth factor
(bFGF)-induced the proliferation, migration and adhe-
sion of endothelial cells and attenuated bFGF-induced
capillary density in mice. Furthermore, a growing body
of evidence indicates that chronic inflammation is con-
sidered to be one of the most important factors contri-
buting to tumor development and progression. Most
solid tumors contain many non-malignant cells, includ-
ing immune and endothelial cells, which are important
in inflammation. Inflammatory cells provide proteases
that facilitate tumor invasion and matrix remodeling,
accompanying with chemokines, growth factors, and
angiogenic factors [6]. Kallistatin prevented inflamma-
tory responses by reducing the accumulation of macro-
phages [7]. Based on these findings, kallistatin has the
potential as a therapeutic agent for the treatment of
tumor. We have recently reported adenoviral vector-
mediated kallistatin expression ameliorated disease pro-
gression in the rat model of rheumatoid arthritis and
osteoarthritis [2,8]. In this study, we exploited lentiviral
vectors carrying kallistatin gene (LV-Kallistatin) as an
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dual effect of anti-angiogenic and anti-inflammatory
activities, LV-Kallistatin has the therapeutic potential for
treatment of lung tumors.
Methods
Cell lines, plasmid, lentivirus and mice
Human rhabdomyosarcoma cells (TE671), 293T and
mouse Lewis lung carcinoma (LL2) were cultured in
Dulbecco’s Modified Minimal Essential Medium
(DMEM) supplemented with 10% cosmic calf serum
( H y c l o n e ,L o g a n ,U t a h ,U S A ) ,2m ML - g l u t a m i n ea n d
50 μg/ml gentamicin at 37°C in 5% CO2. Human umbi-
lical vein endothelial cells (HUVEC) were cultured in
EGM medium (Cambrex, East Rutherford, NJ, USA).
The pcDNA3.1-hKallistatin plasmid was linearized with
HindIII and filled in with Klenow fragment to form
blunt end, and then the human kallistatin fragment was
released with EcoRI from the linearized plasmid. The
human kallistatin expression vector pWPXL-Kallistatin,
under the control of elongation factor 1-a (EF-1a)p r o -
moter, was constructed by cloning the 1.3-kb cDNA
fragment of human kallistatin into the PmeI/EcoRI sites
of pWPXL. To produce recombinant lentiviruses encod-
ing kallistatin or green fluorescence protein (GFP), 293T
cells were transfected with pWPXL-Kallistatin or
pWPXL, together with psPAX2 packaging vector and
pMD2.G envelope vector by calcium phosphate precipi-
tation, and the conditioned medium (CM) containing
viral particles was harvested 48 h after transfection [9].
The titers of virus were determined on TE671 cells by
fluorescence-activated cell sorter (FACS) analysis for
GFP expression (BD Biosciences, San Jose, CA, USA).
Briefly, approximately 2 × 10
5 TE671 cells were plated
in six-well culture dishes and infected with serial 10-fold
dilutions of viral vectors (10
-1 to 10
-5) in serum free
medium. Cells were collected 72 h after infection, and
the number of GFP-positive cells was used to quantify
the titer (transduction unit, TU).
Meanwhile, the titer of viral particles was performed
using the Quick Titer lentivirus titer kit (Cell Biolabs,
San Diego, CA, USA), which measures lentivirus-asso-
ciated HIV p24 by enzyme-linked immunosorbent assay
(ELISA). One ng/ml of lentiviral p24 corresponds to 1 ×
10
5 TU/ml of the GFP-encoding lentiviral vector. The
vector pWPXLLuc was derived from pWPXL where the
GFP cDNA was replaced with firefly luciferase cDNA
obtained from the pGL3-Basic vector (Promega, Madi-
son, WI, USA). The EF1-a promoter was removed from
pWPXLLuc at ClaIa n dSwaI sites and then replaced by
the NF-B responsive elements obtained from pGL2-
IL8, resulting in pWPXL-NF-BLuc [10]. The recombi-
nant lentiviruses encoding luciferase were produced as
previously described. For transduction of LL2 cells with
the luciferase gene, cells were infected with recombinant
lentiviruses carrying luciferase gene under the control of
NF-B responsive elements. As the lentiviral vectors did
not contain selectable markers, luciferase-expressing
stable LL2 clones were identified by monitoring lucifer-
ase expression in each isolated clone. LL2/NF-BLuc
clones with high level luciferase expression were used
for further studies. Male C57BL/6 mice (6-8 weeks old)
were obtained from the Laboratory Animal Center of
the National Cheng Kung University. The experimental
protocol adhered to the rules of the Animal Protection
Act of Taiwan and was approved by the Laboratory Ani-
mal Care and Use Committee of the National Cheng
Kung University. At indicated time points, mice were
sacrificed, and the tissue lysates were assessed for luci-
ferase activity with luciferase reporter gene assay system
(Applied Biosystems, Foster City, CA, USA) using a
luminometer (MiniLumat LB 9506; Berthold Technolo-
gies, Bad Wildbad, Germany).
Cell migration, invasion and proliferation assay
The TE671 cells were infected with lentiviruses encod-
ing GFP (LV-GFP) or LV-Kallistatin in different multi-
plicity of infection (MOI). The virus-containing medium
from the infected cells was removed 8 h post-infection
and fresh medium was added. The expression of kallis-
tatin was verified by ELISA as described previously [11].
Forty-eight h after infection, the supernatant was col-
lected for the migration and proliferation assays. Cell
migration was assessed using a modified Boyden Cham-
ber (Corning Costar, Cambridge, MA, USA). The mem-
brane was coated with gelatin (100 ng/ml) for migration
assay or collagen (100 ng/ml) for invasion assay. VEGF
(10 ng/ml) or bFGF (15 ng/ml) was added at the lower
compartment of the chamber. HUVEC (1 × 10
4 cells/
well) or LL2 cells (1 × 10
4 cells/well) treated with CM
were added to the upper compartment and incubated
for 4 h. The filter was then fixed with 100% methanol
for 8 minutes and stained by Giemsa stain solution for
1 h. Cells were counted randomly three images per well
under a microscope. For the cell proliferation assay,
cells were treated with serum-free medium for 24 h, and
then incubated with 100 μl of CM from TE671 cells
infected with lentiviruses in 10 MOI or mock infection
in the presence of VEGF (10 ng/ml) or bFGF (15 ng/ml)
for 48 h. Cell viability was measured with WST-1 assay
(Dojindo Laboratories, Tokyo, Japan).
Experimental lung metastatic models and
Immunohistochemistry
To determine the expression of kallistatin after LV-
Kallistatin injection, mice were inoculated with LL2 cells
(5 × 10
5) via the tail vein at day 0. LV-Kallistatin, LV-
GFP (10
6 TU), or saline were injected into the mice via
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sue was determined by ELISA at day 17. In the experi-
mental lung metastatic model, mice were injected with
LL2 cells (5 × 10
5) via tail vein at day 0. Then the mice
were treated with lentivirus (10
8 TU) by intravenous
injection at day 1. To detect the protein and cytokine
expressions, the lungs were collected at day 12. Levels
of TNF-a and VEGF in the lung were determined by
ELISA (R & D, Minneapolis, MN, USA). The protein
content in each sample was determined by bicinchoninic
acid (BCA) protein assay (Pierce Biotechnology, Rock-
ford, IL, USA). Moreover, lungs from the tumor-bearing
mice treated with lentivirus (10
8 TU) or saline were col-
lected and weighted at day 25. To analyze infiltrating
macrophages and microvessel density in the tumor sites,
tumor-bearing mice were injected intravenously (i.v.)
with LV-Kallistatin, LV-GFP (10
8 TU), or saline at day
1. The whole tumors were excised and snap frozen at
day 20. Tumor angiogenesis and infiltrating macro-
phages were assessed by immunostaining as previously
described [12].
Statistical analysis
Statistical significance between groups was assessed by the
unpaired Student’s t-test. The survival analysis was per-
formed using the Kaplan-Meier survival curve and the log-
rank test. p < 0.05 were regarded as statistically significant.
Results
Expression of bioactive kallistatin via lentivirus-mediated
gene transfer
To test the feasibility of exploiting recombinant lenti-
viruses for gene delivery in cells, the expression of kallis-
tatin was examined and characterized in TE671 cells
infected with LV-Kallistatin or LV-GFP. TE671 cells
transduced with lentiviral vectors were shown 1.3~2.1
times more efficiently transduction rate than 293T and
HepG2 cells [13]. In this study, TE671 cells were used as
the target cells to express the transgene. ELISA analysis
was performed to examine the protein levels of kallistatin
in the supernatant from TE671 cells. Kallistatin was
detectable in LV-Kallistatin-treated cells, but not in LV-
GFP- or saline-treated cells. To determine the gene
expression in mice, we injected saline, LV-GFP, or LV-
Kallistatin into tumor-bearing mice at day 15 and exam-
ined the expression of kallistatin at day 17. Low levels of
signal in serum, lung, and tumor sites were detected in
the saline-treated and LV-GFP-treated group. After LV-
Kallistatin injection, the expression of human kallistatin
was detected in all examined organs including tumor
sites (Figure 1A). The CM from LV-Kallistatin-infected
cells was tested for bioactive kallistatin. As shown in Fig-
ure 1, the CM from LV-Kallistatin-infected cells signifi-
cantly reduced VEGF- (Figure 1B) and bFGF-(Figure 1C)
Figure 1 Expression of bioactive kallistatin via lentivirus-
mediated gene transfer. (A) Groups of mice were inoculated with
LL2 cells (5 × 10
5) via tail vein at day 0. LV-Kallistatin or LV-GFP (10
6
TU), or saline were injected into tumor-bearing mice via tail vein at
day 15. Mice were sacrificed at day 17, and tissues were harvested
and measured by ELISA (mean ± SD, n = 3). The conditioned
medium (CM) from LV-Kallistatin-infected TE671 cells inhibited (B)
VEGF-induced and (C) bFGF-induced the proliferation of human
umbilical vein endothelial cells (HUVEC). HUVEC (4 × 10
3/well) were
treated with serum-free medium for 24 h, and then incubated with
100 μl CM in the presence of VEGF (10 ng/ml) or bFGF (15 ng/ml)
for 48 h. Cell viability was measured with WST-1 assay. (mean ± SD,
n = 4, * p < 0.05,**p < 0.01, ***p < 0.001)
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tive phenotype was in a dose-dependent manner.
Together, these results showed that lentivirus-mediated
gene transfer could produce biological active kallistatin.
Kallistatin inhibits the proliferation and invasion of tumor
cells
Recombinant lentiviral vectors can transduce genes with
great efficiency. Furthermore, systemic administration of
lentiviruses resulted in the major transgene production
in livers (Figure 1A) [14]. The results point out that
host tissues can be transduced with lentiviral vectors
and contribute to transgene production. We used the
CM system in vitro to mimic the microenvironment
in vivo. Figure 2A demonstrated that proliferation of
LL2 cells was dramatically decreased upon addition of
the CM from LV-Kallistatin-infected cells compared
with that from LV-GFP-infected counterparts. Mean-
while, kallistatin in the CM dramatically reduced VEGF-
or bFGF- induced LL2 cell migration and invasion
(Figures 2B and 2C). In addition, the proliferation of
LL2 cells was inhibited by LV-Kallistatin infection
(Additional file 1). Taken together, these observations
suggested that kallistatin inhibited the proliferation,
migration, and invasion of tumor cells.
Reduced metastatic nodules and prolonged survival in
mice bearing experimental pulmonary metastatic tumors
were obtained by systemic delivery of lentiviral vectors
carrying kallistatin gene
Since inhibition of metastatic tumor is still a major chal-
lenge for tumor treatment, we next investigated whether
LV-Kallistatin could inhibit pulmonary tumor nodules.
The in vivo antitumor effects of LV-Kallistatin were evalu-
ated in terms of tumor growth and survival in mice bear-
ing metastatic pulmonary nodules. We injected mice with
LL2 cells via tail vein at day 0, and then treated them i.v.
with LV-Kallistatin, LV-GFP or saline at day 1 after tumor
inoculation. Tumor-bearing mice were sacrificed at day 25
to determine the wet lung weight for quantifying the
t u m o rb u r d e ni nt h el u n g s .A ss h o w ni nF i g u r e s3 Aa n d
3B, the tumor nodules and total lung weight were dramati-
cally reduced in LV-Kallistatin-treated mice. The lung
weight of mice treated with LV-Kallistatin was 35% less
than that treated with LV-GFP or saline. Meanwhile, the
treatment of LV-Kallistatin prolonged the survival of mice
with pulmonary metastasis (Figure 3C). Results of this
study showed that systemic delivery of LV-Kallistatin
delayed tumor growth and prolonged mice survival.
Inhibition of tumor angiogenesis by LV-Kallistatin
Microvessel density within the tumors was analyzed
by immunohistochemistry at day 20. Tumors from
Figure 2 Kallistatin reduced the proliferation, migration, and
invasion of LL2 cells. The CM derived from various-treated cells
was diluted in serum-free medium at 1:1 and incubated with LL2
cells. (A) Cell viability was assessed by the WST-1 assay. The
percentage of surviving cells (mean ± SD, n = 6) was calculated by
comparing surviving cells of the CM-treated cells to saline-treated
cells. Migration (B) and invasion (C) of LL2 cells (10
4) were examined
by using a 48-well Boyden chemotaxis chamber with membranes
coated with gelatin (B) or collagen (C). (mean ± SD, n = 5,
*p < 0.05, **p < 0.01)
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than those from LV-GFP- or saline-treated counterparts,
whereas no such difference was found between LV-
GFP- and saline-treated groups (Figures 4A and 4B).
Microvessel density in tumors receiving LV-Kallistatin
reduced to 40% as compared with that in LV-GFP-
injected group (19 ± 8 vessels/mm
2,n=1 0v e r s u s1 0±
4 vessels/mm
2, n = 11) and in saline-injected group (19
± 5 vessels/mm
2, n = 11 versus 10 ± 4 vessels/mm
2,n=
11). These results demonstrated that kallistatin gene
delivery markedly suppressed the angiogenic response in
the tumor sites.
Effects of kallistatin on inflammation in tumor
Tumor progression depends, in part, on the density of
tumor-associated macrophages (TAMs). There is a cor-
relation between TAM abundance and poor prognosis
[15]. TAMs are highlighted as not only a major partici-
pator but also an important regulator of inflammation.
These macrophages actually promote the proliferation
and metastasis of tumor cells by secreting a wide range
of growth and pro-angiogenic factors, as well as pro-
inflammatory cytokines [16]. In present study, the distri-
bution of macrophages in the tumor sites was assayed
by immunostaining. The numbers of infiltrating macro-
phages in mice treated with LV-Kallistatin were signifi-
cantly decreased in comparison with those in mice
treated with LV-GFP or saline (Figures 5A and 5B). As
macrophages are major cytokine-secreting cells, we next
examined the levels of TNF-a and VEGF in tumor
microenvironment after different treatments. Tumors
from LV-Kallistatin group contained lower concentra-
tions of TNF-a and VEGF than those from control
groups (Figures 5C and 5D). The presence of macro-
phages in solid tumors suggests that tumors grow at the
sites of chronic inflammation. NF-B signaling might
play an important role in inflammation and tumor pro-
gression. To assess the activation of NF-B signal trans-
duction pathway, we performed a reporter assay using
lentivirus-transduced LL2 cells containing the luciferase
gene under the control of NF-B responsive elements
in vivo. LL2/NF-BLuc cells were injected into the tail
vein of mice, and the luciferase activity from lungs was
determined. Figure 5E showed that luciferase gene
expression was high, indicative of higher NF-B activity,
in the lungs of mice treated with saline or LV-GFP. Kal-
listatin inhibited the NF-B transcriptional activity in
tumor. These results suggest a potential role for kallista-
tin in the anti-inflammation and anti-angiogenesis,
which may contribute to the inhibition of tumor growth.
Discussion
Results of this study show that LV-Kallistatin inhibits
the growth of orthotopic lung tumor via systemic
administration. The expression of kallistatin in the
tumor-bearing mice, which leads to decreased intratu-
moral microvessel density and chronic inflammation,
may contribute to the antitumor effect of LV-Kallistatin
on lung tumor. We demonstrated that intravenous
administration of LV-kallistatin inhibited the tumor
growth. However, complete tumor regression was not
observed in the LV-Kallistatin-treated mice, and mice
Figure 3 LV-Kallistatin retarded tumor growth and enhanced the mice survival. Groups of mice were inoculated with LL2 cells (5 × 10
5)
via tail vein at day 0. LV-Kallistatin or LV-GFP (10
8 TU), or saline were injected to mice via tail vein at day 1. Mice were sacrificed at day 25, and
their lungs were photographed (A) and weighed (B) (mean ± SD, n = 8~9). Note that the numbers and sizes of tumor nodules indicated by
arrows were reduced in mice treated with LV-Kallistatin compared with those treated with LV-GFP or saline group. (C) Kaplan-Meier survival
curves of tumor-bearing mice with various treatments are shown. (n = 7~8). (*p < 0.05, **p < 0.01, ***p < 0.001)
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Different tumors may respond diversely to the angio-
genic inhibitors [17,18]. Bergers et al.s h o w e dt h a tv a r -
ious angiogenic inhibitors have distinct efficacy profiles
depending on the stage of tumor development and
probably the kinetics of cell growth [19].
Moreover, the anti-vector immunity is a potential
issue for cancer gene therapy based on multiple systemic
injections. The immunocompetent host previously
exposed to the vector may cause their relative lack of
efficacy. The lentiviral vectors, peudotyped with vesicu-
lar stomatitis virus glycoprotein (VSV-G), have been
shown to be less sensitive to anti-vector neutralizing
antibody, while displaying desirable characteristics, such
as transduction of non-dividing cells, and long-term
transgene expression [20,21]. However, in our previously
studies, we injected adenovirus carrying kallistatin gene
into knees of rats once per week for 3 weeks, and found
the expression of transgene 10 days after the last virus
administration. Our studies did not find any evidence of
anti-kallistatin antibody in the treated animals [8].
A possible explanation for the limited transgene-trig-
g e r e di m m u n er e s p o n s ei st h a tt h ekallistatin gene is
conserved in chimpanzee, dog, rat, and mouse [22,23].
The human kallistatin is very similar to mouse endogen-
ous kallistatin. The anti-kallistatin neutralizing antibo-
dies may not be produced dramatically during the short
course of treatment. Accordingly, multiple injections of
the recombinant lentiviruses are most likely to increase
the kallistatin production, and enhance the antitumor
activity in the short course of treatment.
Previously, human kallistatin levels were determined
by ELISA in various human organs. The kidney had
highest concentration of kallistatin, followed by liver,
lung, prostate gland, and colon (34.8~130.5 ng/mg pro-
tein) among human tissues [24]. In our system, the tis-
sue distribution of kallistatin in control mice was
determined at higher concentrations in livers (27.0 ± 7.3
ng/mg), lungs (12.1 ± 3.9 ng/mg), and a lower concen-
trations in tumor sites (7.0 ± 5.0 ng/mg) by using
human kallistatin ELISA system. Because we used poly-
clonal antibody against human kallistatin in ELISA sys-
tem, the signals appeared in saline- and LV-GFP-treated
mice were due to a cross-reaction. The expression of
transgene in mouse tissues after systemic administration
of LV-Kallistatin was determined by using human
Figure 4 Inhibition of angiogenesis in tumors by lentiviruses carrying kallistatin gene. Groups of mice were inoculated with LL2 cells
(5 × 10
5) via tail vein at day 0. LV-Kallistatin or LV-GFP (10
8 TU), or saline were injected into mice via tail vein at day 1. (A) Lungs were excised at
day 20, snap frozen and immunostaining with rabbit antibody against factor VIII-related antigen (×200). (B) Intratumoral microvessel density was
determined by averaging the number of vessels in three areas of highest vessel density at × 200 magnification in each section. (mean ± SEM,
n=3* p < 0.05, **p < 0.01, ***p < 0.001).
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mouse kallistatin remains to be investigated by using
specific mouse kallistatin detective system.
Meanwhile, we found that kallistatin could inhibit the
proliferation and migration of tumor cells. Indeed, it has
been demonstrated that VEGF directly stimulates the
growth of tumor cells [25]. Kallistatin inhibits the prolif-
eration of endothelial cells and reduces production of
paracrine factors, thus suppresses the proliferation of
tumor cells. Our results found that VEGF could induce
the migration and invasion of tumor cells (Figures 2B
and 2C). Kallistatin may act by competing with VEGF
and binding to heparin-sulfate proteoglycans [5]. Kallis-
tatin suppresses VEGF-binding activity and angiogenic
signaling cascades induced by VEGF. The anti-angio-
genic effect of kallistatin may be similar to anti-VEGF
antibody treatment pruning immature vessels in tumor
sites. The vessel normalization and restoration of pres-
sure gradients induced by VEGF blockade may explain
the increased uptake of antitumor drugs and oxygen in
tumor sites [26]. Furthermore, it has been reported that
meloxicam augmented the antitumor activity of kallista-
tin [27]. Anti-angiogenic agents may contribute to
improve the hypoxic condition of tumor sites by vascu-
lar normalization [28]. Hypoxia, a hallmark of many
solid tumors, was reduced by angiogenic inhibitors [29].
Therefore, it was showed that kallistatin had the ability
to reduce hypoxia inducible factor (HIF)-1 a expression
[4], and may improve the hypoxic condition in the
tumor microenvironment and increase the radiation or
chemotherapy effects.
Several activities of kallistatin contribute to its antitu-
mor effects. Kallistatin has ability to inhibit the inflam-
mation and also reduce the intracellular superoxide
Figure 5 LV-Kallistatin inhibited the inflammation in tumors. Mice bearing LL2 or LL2/NF-BLuc tumors at day 0 were injected with LV-GFP,
LV-Kallistatin (10
8 TU) or with saline at day 1. (A) Tumors were excised at day 20, immunostained with antibodies against F4/80 (×200). (B)
Macrophages were determined by averaging the cell numbers from three fields of highest positive-stained cell density at ×200 magnification in
each section (mean ± SEM, n = 3~4). (*p < 0.05) Tumor-bearing mice were treated with LV-Kallistatin, LV-GFP (10
8 TU) or saline, and their lungs
were collected at day 12. The levels of TNF-a (C), and VEGF (D) were measured by using ELISA. (E) The luciferase activities in tumors were
measured at day 17. (mean ± SD n = 3~4, *p < 0.05, **p < 0.01).
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activity by kallistatin probably contribute to the anti-
inflammatory activity. The effector cells involved in
enhancing tumor growth appear to be macrophages,
which are recruited to the tumor sites and produce
TNF-a to stimulate tumor growth [30,31]. Our results
found that kallistatin reduced the infiltrating macro-
phages, TNF-a production and NF-B transcriptional
activity in tumor sites. These findings suggest that kallis-
tatin may affect the macrophages and provide a new
insight regarding to the relation between inflammation
and tumor. Therefore, it is plausible that the antitumor
effect of LV-Kallistatin may be attributed not only to its
effects on tumor endothelial cells, but also to its ability
to down-regulate inflammation within the tumor sites.
In agreement with previous reports, our results show
that systemic administration of anti-angiogenic inhibi-
tors to tumor-bearing animal results in down-regulation
of VEGF expression in tumors [32,33]. In our studies,
we did not observe any toxicity/side effects in animals,
and the healthy lung did not show any toxic effect after
LV-Kallistatin treatment. Therefore, combining our pre-
vious data with present ones, we suggest that lentivirus
carrying kallistatin gene may be further explored as an
anticancer agent for primary and metastatic tumors.
Conclusion
We have demonstrated that kallistatin gene delivery can
be achieved by systemic administration of lentiviral vec-
tors carrying kallistatin gene and the gene expression
can inhibit tumor growth and enhance survival in estab-
lished metastatic murine lung tumor models. By taking
advantages of the anti-angiogenic and anti-inflammatory
effects of kallistatin, kallistatin gene therapy appears to
hold promise for the treatment of solid tumors.
Additional file 1: LV-Kallistatin inhibited the proliferation of tumor
cells. LL2 cells (10
5) were treated with saline, LV-GFP, or LV-kallistatin
(10
6 TU) for 48 h. Cell viability was measured with WST-1 assay. The
percentage of surviving cells was calculated by comparing surviving cells of
the virue-treated cells to saline-treated cells. (mean ± SD, n = 4, **p <0 . 0 1 )
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